AI Article Synopsis

  • There is a significant lack of data on antipsychotic prescribing and usage in Pakistan, highlighting the need for strategies to improve availability, affordability, and address issues like gender differences and domestic violence.
  • A study analyzed antipsychotic use from 2010 to 2015, finding a 4.3-fold increase in utilization and a 13.2% rise in cost per unit, with risperidone and olanzapine being the most commonly prescribed.
  • The research revealed limited polypharmacy, with an average of 4.56 medicines per encounter, but raised concerns about the continued use of typical antipsychotics due to comorbidities and the need to examine prescribing practices and gender disparities.

Article Abstract

There is a paucity of antipsychotic prescribing and utilization data in Pakistan that needs addressing, especially with issues of availability, affordability, gender differences, and domestic violence, to develop pertinent strategies. The objective of this study was to address these issues by describing current antipsychotic utilization patterns in Pakistan among adult patients attending tertiary care hospitals and private practitioners. A three staged approach was used including (1) assessment of total antipsychotic utilization, expenditure, and costs per unit between 2010 and 2015, (2) an in-depth retrospective study of prescribing patterns, including co-morbidities among representative hospital patients in Pakistan, and (3) assessment of the quality of prescribing against WHO targets. Total use of antipsychotics increased 4.3-fold and the cost/unit increased by 13.2% during the study period. Risperidone and olanzapine were the most prescribed antipsychotics with more limited use of other typical and atypical antipsychotics. The number of medicines per encounter was 4.56. Prescription using generic instead of brand names was 21.4%. Seven per cent were prescribed more than one antipsychotic concurrently. There has been an appreciable increase in antipsychotic utilization in recent years in Pakistan, especially atypical antipsychotics, with little polypharmacy. Ongoing utilization of typical antipsychotics may be due to comorbidities such as diabetes and cardiovascular disease. Issues of international non-proprietary name prescribing need investigating along with the high number of medicines per encounter and gender inequality.

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2018.1513834DOI Listing

Publication Analysis

Top Keywords

antipsychotic utilization
12
atypical antipsychotics
8
number medicines
8
medicines encounter
8
antipsychotic
6
pakistan
5
utilization
5
antipsychotics
5
trends prescribing
4
prescribing antipsychotic
4

Similar Publications

Mental Health Utilization Among Transgender Veterans.

JAMA Netw Open

January 2025

VA Center for Health Information and Communication, US Department of Veterans Affairs, Veterans Health Administration, Health Systems Research CIN 13-416, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana.

Importance: Compared with cisgender (CG) individuals, transgender and gender-diverse (TGD) individuals experience substantial social and economic disparities that can result in adverse mental health consequences. It is critical to understand potential barriers to care and to address the causes of the disparities in the future.

Objective: To characterize mental health care utilization among TGD veterans with depression.

View Article and Find Full Text PDF
Article Synopsis
  • The negative symptoms of schizophrenia, like lack of emotion and motivation, are hard to treat and significantly impact daily functioning.
  • This review highlights current research on treatment options for these symptoms, categorizing them into different types and evaluating various assessment scales.
  • Although no treatments are conclusively proven as the best for these symptoms, some off-label and investigational medications show promise, including cariprazine and memantine, and further research is needed to explore new therapeutic possibilities.
View Article and Find Full Text PDF

Introduction: Droperidol is a dopamine-2 receptor antagonist in the class of butyrophenone antipsychotics with antiemetic, sedative, analgesic, and anxiolytic properties. In the postoperative setting, droperidol provides an opioid sparing effect and decreases nausea/vomiting. Another butyrophenone antipsychotic, haloperidol, has been shown to reduce morphine milliequivalents (MME) administered when used for abdominal pain in the emergency department (ED).

View Article and Find Full Text PDF

Background: Few new psychiatric drugs have entered the market in recent decades; in contrast, the number of drugs carrying pharmacogenomic labels continues to increase. For the foreseeable future, the advancement of psychiatry and drug therapy may hinge on personalized treatment. Currently, antipsychotic or antidepressant choices rely heavily on the clinical experience of psychiatrists and potentially lengthy iterative trials.

View Article and Find Full Text PDF

Importance: The prevalence of pharmacies owned by integrated insurers and pharmacy benefit managers (PBMs), or insurer-PBMs, is of growing regulatory concern. However, little is known about the role of these pharmacies in Medicare, in which pharmacy network protections may influence market dynamics.

Objective: To evaluate the prevalence of insurer-PBM-owned pharmacies and the extent to which insurer-PBMs steer patients to pharmacies they own in Medicare.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!